EP 614 : Europe Invests €388M in Bull AI Supercomputer as FDA Approves Pancreatic Cancer Pill

What happens when a continent throws billions at AI hardware just as a breakthrough drug reshapes a deadly disease? In this episode we break down the two headline‑grabbing stories that could redefine the tech‑health landscape.First, Europe’s bold €387.8 million gamble on Bull’s LUMI‑AI supercomputer. Backed by EuroHPC and a six‑nation consortium, the new machine will sit beside Finland’s LUMI system and bring AMD chips, IBM storage and Nokia networking under one roof. We explore why this public‑infrastructure push matters, how it narrows the AI compute gap with the U.S. and China, and what it means for European startups and researchers hoping to train the next generation of frontier models.Next, the FDA’s green light for daraxonrasib – a twice‑daily pill that targets the once‑undruggable KRAS mutation in advanced pancreatic cancer. Patients on the drug are now seeing median survival of over 13 months, nearly double the chemotherapy baseline. We talk to experts about the science behind KRAS inhibition, the potential ripple effects for other hard‑to‑treat cancers, and what this milestone means for patients, clinicians, and investors.We also skim the week’s other AI & science buzz: MIT’s hybrid electric aircraft, Rainmaker’s drone‑based cloud‑seeding that claims 19 million gallons of rain, and a new UCSF brain‑protein map that could finally point to autism therapies. Finally, we highlight the top AI productivity tools that are helping creators and engineers stay ahead of the curve.Tune in for a deep dive, share with colleagues who love cutting‑edge tech and health news, and hit subscribe so you never miss a story that sits at the intersection of innovation and impact.Tools mentioned: akta.pro, Skydive, Diet Claude, Enter Pro, Decawork.